Apocynin alleviates weight gain and obesity‐induced adipose tissue inflammation in high‐fat diet‐fed C57BL/6 mice

Abstract Obesity involves chronic low‐grade inflammation within adipose tissue. Apocynin (APO) is a therapeutic agent for the treatment of inflammatory diseases. Therefore, the present study aimed to investigate whether APO can reduce weight gain and obesity‐induced adipose tissue inflammation. C57BL/6 mice were administered APO or orlistat (Orli) as a positive control with a high‐fat diet (HFD) for 12 weeks. Lipopolysaccharide‐stimulated 3T3‐L1 adipocytes were used for the in vitro study. Our results showed a significantly lower white adipose tissue (WAT) mass index in 10 mg/kg APO‐treated mice than in 20 mg/kg Orli‐treated mice. Moreover, the protein expression of adipose triglyceride lipase, fatty acid synthase, sterol regulatory element‐binding transcription factor 1, and peroxisome proliferator‐activated receptor γ was reversed in the WAT of 10 mg/kg APO‐treated mice. Furthermore, APO reduced the expression of the macrophage marker F4/80, decreased the mRNA levels of tumor necrosis factor‐α and monocyte chemoattractant protein‐1, and increased the mRNA levels of interleukin‐10 in WAT. APO decreased the phosphorylation of c‐Jun N‐terminal kinase, extracellular signal‐regulated kinase, and p65 in vivo and in vitro. Notably, APO had a stronger effect on the amelioration of adipose tissue inflammation than Orli did. Our findings lay the foundation for research on the use of APO as an agent to ameliorate weight gain and obesity‐induced inflammatory diseases.